Apresentação clínica da Doença de Creutzfeldt-Jakob como Síndrome Cerebelar
DOI:
https://doi.org/10.34024/rnc.2009.v17.8606Palavras-chave:
Doença de Creutzfeldt-Jakob, Demência, Doenças de PríonResumo
A doença de Creutzfeldt-Jakob (DCJ) constitui-se na mais comum das doenças priônicas em seres humanos. Apresentamos um caso de DCJ tipo esporádico em um homem de 48 anos, que iniciou quadro de síndrome cerebelar, cuja clínica evoluiu compatível com DCJ associado à alteração do eletroencefalograma (EEG) típica e líquor (LCR) com alteração da proteína 14-3-3. São discutidos os métodos diagnósticos, as expectativas sobre a identificação de fatores de transmissão e a terapêutica atual.
Downloads
Métricas
Referências
Tyler KL. Creutzfeldt-Jakob Disease. N Engl J Med 2003;348:681.
Araújo ABQ, Oliveira ALA. Doenças por prions. Rev Neurocienc 1998;6:33-46.
Prusiner SB. Shattuck lecture: Neurodegenerative diseases and prions. N Engl J Med 2001;344:1516-26.
Brown P, Gibbs CJ Jr, Rodgers-Johnson P, Asher DM, Sulima MP, Bacote A, et al. Human spongiform encephalopathy: the National Institutes of Heatlh series of 300 cases of experimentally transmited disease.
Ann Neurol 1994;35:513-29.
Zeidler M, Stewart GE, Barraclough CR, Bateman DE, Bates D, Burn DJ, et al. New variant Creutzfeldt-Jakob disease: neurological features and diagnosis tests. Lancet 1997;350:930-7.
Epstein LE, Brown P. Bovine spongiform encephalopathy and a new variant of Creutzfeldt Jakob disease. Neurology 1997;48:569-71.
Chiarini LB, Freitas ARO, Zanta SM, Brentani RR, Martins VR, Linden R. Celular prion protein transduces neuroprotective signals. EMBO 2002;21:3317-26.
Huang N, Marie SK, Livramento JA, Chammas R, Nitrini R. 14-3-3 protein in the CSF of patients with rapidly progressive dementia. Neurology 2003:61;354-1.
Brandel JP, Delasnerie-Lauprêtre N, Laplanche JL, Hauw JJ, Alpérovitch A. Diagnosis of Creutzfeldt Jakob disease. Neurology 2000;54:1095-9.
Kovacs T, Arányi Z, Szirmai I, Lantos PL. Creutzfeldt Jakob disease with amyotrophy and demyelinating polyneuropathy. Arch Neurol 2002;59:1811-4.
Steinhoff BJ, Rãcker S, Herrendorf G, Poser S, Grosche S, Zerr I, et al. Accuracy and reability of periodic sharp wave complexes in Creutzfeldt-Jakob disease. Arch Neurol 1996;53:162-6.
Moretti R, Torre P, Nasuelli D, Ferretti G, Antonello RM, Povolato M, et al. Diagnostic instruments for Creutzfeldt Jakob disease. Eur J Neurol 2000;7:363-4.
Hsich G, Kenney K, Gibbs CJ, Lee KH, Harrington MG. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 1996;335:924-30.
Krovanen J, ErkinJuntti T, Ivanaimen M. Cerebral MR and CT imaging in Creutzfeldt-Jakob disease. J Comput Assist Tomogr 1985;9:125-8.
Bahn MM, Parchi P. Abnormal diffusion-weighted magnetic resonance images in Creutzfeldt-Jakob disease. Arch Neurol 1999;56:577-83.
Hill AF, Butterworth RJ. Joiner S, Jackson G, Rossor MN, Thomas DJ, et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsill biopsy samples. Lancet 1999;353:183-4.
Will RG, Cousens SN, Farrington CO, Smith PG, Knight RSG, Ironside JW. Deaths from variant Creutzfeldt Jakob disease. Lancet 1999;353:979.
Poser S, Mollenhauer B, Kraub A, Zerr I Steinhoff BJ, Schroeter A, et al. How to improve the clinical diagnosis of Creutzfeldt-Jakob disease. Brain 1999;122:2345-51.
Brown P. Drug therapy in human and experimental transmissible spongiform encephalopathy. Neurology 2002;58:1720-5.
Downloads
Publicado
Como Citar
Edição
Seção
Publicado: 2009-03-31
Português
English
Español
